Targeting IDH in Low-Grade Glioma

N Engl J Med. 2023 Aug 17;389(7):655-659. doi: 10.1056/NEJMe2305602.

Authors

Elizabeth B Claus¹, Roel G W Verhaak¹

Affiliation

¹ From the School of Public Health (E.B.C.) and the Department of Neurosurgery, School of Medicine (E.B.C., R.G.W.V.), Yale University, New Haven, CT; the Department of Neurosurgery, Brigham and Women's Hospital, Boston (E.B.C.); and the Department of Neurosurgery, Amsterdam University Medical Center, Amsterdam (R.G.W.V.).

PMID: 37585633
DOI: 10.1056/NEJMe2305602

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Agents* / therapeutic use
Brain Neoplasms* / drug therapy
Brain Neoplasms* / genetics
Brain Neoplasms* / pathology
Glioma* / drug therapy
Glioma* / genetics
Glioma* / pathology
Humans
Isocitrate Dehydrogenase* / genetics
Molecular Targeted Therapy* / methods
Mutation
Neoplasm Grading

Substances

Isocitrate Dehydrogenase
Antineoplastic Agents